Roche withdraws bladder cancer indication for blockbuster Tecentriq
The decision by Roche comes shortly after AstraZeneca withdrew the bladder cancer indication for durvalumab (Imfinzi).
One month after AstraZeneca made a similar decision, Roche is voluntarily withdrawing its US indication for atezolizumab (Tecentriq) for prior-platinum treated metastatic urothelial carcinoma (mUC) or bladder cancer.
The decision was made in consultation with FDA as part of an industrywide review of accelerated approvals with confirmatory trials that have not met their primary endpoint and have yet to gain regular approvals, Roche said in a press release.
Related:Biosimilar to Rituxan expected to hit market in January
Tecentriq had nearly $3 billion in sales in 2020, Reuters reported.
In February, AstraZeneca voluntarily withdrew durvalumab’s (Imfinzi) indication for locally advanced or metastatic bladder cancer.
Levi Garraway
“The Accelerated Approval Program allows people with difficult-to-treat cancers to receive certain new therapies earlier,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of global product development at Roche. “While the withdrawal of Tecentriq for prior-platinum treated bladder cancer is disappointing, Tecentriq continues to demonstrate benefits across multiple cancer types and therefore remains a meaningful treatment option for many patients.”
Related: FDA clears Orgovyx, the first-of-its-kind prostate cancer treatment
FDA's Accelerated Approval Program allows conditional approval of a medication that fills an unmet medical need for a serious condition, with specific post-marketing requirements (PMRs) to confirm the clinical benefit.
FDA granted Tecentriq accelerated approval in 2016 to treat prior-platinum treated mUC based on the results from the IMvigor210 study. Continued approval for this indication was contingent upon the results of IMvigor211, the original PMR for the prior-platinum treated mUC indication, Roche said.
However, that study did not meet its primary endpoint of overall survival in the PD-L1 high patient population, according to Roche.
Read more: FDA fast-tracks investigational leukemia treatment
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
FDA Approves Tevimbra for Advanced Esophageal Cancer at $15,828 Per Month
March 5th 2025Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that by 2040, there will be approximately 957,000 new cases of esophageal cancer worldwide, marking a nearly 60% increase from 2020, according to BeiGene.
Read More
